Remove Article Remove Clinical Research Remove Regulations
article thumbnail

“Nothing scares us” – Ukraine’s clinical research sector begins fearless recovery

Drug Discovery World

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+ Dr Olena Karpenko.

article thumbnail

Understanding the Impact of the New EU Artificial Intelligence Act on Clinical Research

Advarra

Artificial intelligence (AI) has taken the world by storm – and regulators are paying attention. The EU AI Act’s implications extend into clinical research, where AI is increasingly utilized for tasks like medical image analysis, natural language process for endpoint analysis, and generating/analyzing data for synthetic control arms.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Incentivizing Participation: The Evolving Role of Patient Payments in Clinical Research

Vial

Clinical research is an integral component of the healthcare ecosystem. The success of clinical research hinges crucially on patient participation; however, attracting and retaining participants can often pose significant challenges. Patient Payments in Clinical Research: Perception Over the Years In the U.S.,

article thumbnail

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. What is a Pre-Clinical CRO?

article thumbnail

Article FDA: FDA’s informed consent guidance gets a 21st century makeover

Agency IQ

The new guidance offers recommendations for institutional review boards (IRBs), investigators and sponsors on key aspects of informed consent, significantly expanding FDA’s recommendations on several key topics, including reimbursement for research participation. The FDA, HHS, and research and informed consent policies In the U.S.,

FDA 52
article thumbnail

Kaempferol exerts antioxidant effects in age?related diminished ovarian reserve by regulating the HSP90/NRF2 pathway

Chemical Biology and Drug Design

Kaempferol exerted antioxidant effects in AR-DOR by inhibiting Hsp90 to up-regulate Nrf2. In this study, 36 volunteers and 78 DOR patients (37 patients with EXD treatment) were enrolled in the clinical research. This study provides a theoretical basis for the clinical application of kaempferol in AR-DOR.

article thumbnail

Article FDA Thank You FDA AdComm to discuss patient-centric informed consent

Agency IQ

FDA AdComm to discuss patient-centric informed consent The FDA’s Center for Devices and Radiological Health (CDRH) will soon convene its Patient Engagement Advisory Committee to discuss “patient-centered informed consent” policies – notably, not just for medical devices but for “FDA regulated medical products” writ large.

FDA 40